Illustrative Revenue Financings
Software & Solutions
Two representative structures showing how non-dilutive capital adapts to where a company is in its commercialization arc — from first launch to next-generation expansion.
Medtech
Funding Platform Expansion from Existing Revenue
Company profile
Commercial-stage surgical technology company
Situation
First-generation product launched successfully with strong surgeon adoption and growing revenue (~$30M run rate).
Next-generation instrument approaching regulatory submission.
Next-generation instrument approaching regulatory submission.
Capital need
$25M to fund manufacturing expansion, clinical evidence generation, and regulatory submission.
Structure
• $25M investment
• 8% royalty on revenue from the first & second commercial product
• 2.25× capped return
• Royalty terminates once cap is reached or at term
• 8% royalty on revenue from the first & second commercial product
• 2.25× capped return
• Royalty terminates once cap is reached or at term
Strategic Outcome
Existing product revenue funds development of the next platform without equity dilution or governance transfer.
Schedule a meeting
Learn more
Biotech
Financing First Commercial Launch
Company profile
Late-stage oncology biotech approaching FDA approval
Situation
Positive Phase III data and NDA submission create a near-term launch opportunity.
Capital need
$25M to fund commercial build-out, manufacturing scale-up, and working capital during launch ramp.
Structure
• $25M investment
• 6.5% royalty on product revenue
• 2.25× capped return
• Royalty terminates once cap is reached or at term
• 6.5% royalty on product revenue
• 2.25× capped return
• Royalty terminates once cap is reached or at term
Strategic Outcome
Launch financed without dilution, preserving ownership ahead of commercialization.
Schedule a meeting
Learn more
Financing structured around The inflection point.
SVRN's experts partner with life sciences companies to design non-dilutive financings tailored to the moment — whether that's a commercial launch, a label expansion, or a pivotal scale-up.
Our financings are designed for:
Late-clinical to commercial-stage biopharma, medtech, and diagnostics companies.
Companies with near-term or existing revenues and clear product-level cash flows
Management teams seeking non-dilutive growth capital without loss of strategic control
Ask us a question
Learn more
The Commercialization Capital Gap
Find clear, straightforward answers to the most common questions about our approach. SVRN provides structured, non-dilutive capital to life sciences companies through synthetic capped royalty and revenue-based financing.
Why is there a financing gap in biomedical commercialization?
Where is the funding gap most persistent?
When is revenue financing most attractive?
Why revenue financing vs. equity and debt?
What is synthetic royalty financing?
